Since preclinical studies demonstrated that dual inhibition of MEK and Akt can abolish RAS signaling [168,169], selumetinib and MK-2206 have been combined to evaluate drug toxicities and anti-tumor activity in patients with KRAS mutations. Here, MAP2K7 is linked to neoplasm.